Elicio Therapeutics: HC Wainwright Raises PT to $13, Maintains Buy Rating

Elicio Therapeutics: HC Wainwright Raises PT to $13, Maintains Buy Rating

On July 2, 2025, Elicio Therapeutics saw a significant boost in its stock performance, driven by an updated price target from HC Wainwright & Co. The investment bank raised its price target for Elicio Therapeutics to $13, while maintaining a "Buy" rating. This move reflects the analyst's optimistic outlook on the company's prospects and the potential of its pipeline of therapies.

Elicio Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for various indications, including cancer and autoimmune diseases. The company's lead candidate, ELI-201, is a promising investigational therapy for lupus, which has garnered attention from analysts due to its potential to address unmet medical needs.

The updated price target from HC Wainwright & Co. is a notable development, as it underscores the analyst's confidence in Elicio Therapeutics' ability to deliver on its pipeline and achieve market success. The "Buy" rating from the investment bank further signals its belief in the company's long-term growth potential.

In the past few months, Elicio Therapeutics has made significant strides in advancing its pipeline and demonstrating the potential of its therapies. The company's latest clinical data and positive corporate developments have contributed to the positive sentiment surrounding the stock. However, investors should remain vigilant and closely monitor the company's progress as it continues to navigate the complexities of the biotechnology sector.

In summary, the updated price target and "Buy" rating from HC Wainwright & Co. reflect the analyst's bullish outlook on Elicio Therapeutics' prospects. The company's innovative pipeline and promising lead candidate, ELI-201, are key drivers of this optimism. As Elicio Therapeutics continues to make progress in its clinical development efforts, investors will be closely watching the company's performance and the broader market sentiment.

References:
[1] https://www.ainvest.com/news/serina-therapeutics-soars-16-48-analyst-buy-rating-2507/
[2] https://www.tipranks.com/stocks/fate/forecast